Fig. 1: Glioblastoma progression was accompanied by increased CXCL12 in glioblastoma cells and myeloid cells. | Cell Death & Disease

Fig. 1: Glioblastoma progression was accompanied by increased CXCL12 in glioblastoma cells and myeloid cells.

From: CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity

Fig. 1

A Pathway analysis of RNA array of 14 paired naïve-recurrent specimens from high-grade glioma patients, including 2 pairs with grade III features (GBM 001 and 002) and 2 pairs with IDH1 mutation (GBM 012 and 015); B The fold change of individual genes of the neuroinflammation signaling pathway by a heatmap in the recurrent gliomas; C CXCL12 expression in TCGA-glioblastoma dataset; D CXCL12 expression in CGGA-mRNA325 dataset; E UMAP of cell annotation of naïve glioblastoma patient-derived scRNA seq dataset; F the expression distribution and heatmap of CXCL12 and PD-L1 in naïve glioblastoma patient-derived scRNA seq dataset; G The correlation of CXCL12 and PD-L1 in CGGA dataset. CXCL12 expression in B and C was compared by using an unpaired t test. The correlation of CXCL12 and PD-L1/CD274 was analyzed by the Pearson correlation coefficient.

Back to article page